Cornercap Investment Counsel Inc. Sells 11,611 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Cornercap Investment Counsel Inc. lessened its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 52.8% in the 3rd quarter, Holdings Channel.com reports. The fund owned 10,395 shares of the specialty pharmaceutical company’s stock after selling 11,611 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Collegium Pharmaceutical were worth $402,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. increased its stake in Collegium Pharmaceutical by 31.8% in the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after buying an additional 821,541 shares during the period. Rubric Capital Management LP increased its stake in Collegium Pharmaceutical by 27.2% in the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after buying an additional 499,473 shares during the period. Vanguard Group Inc. increased its stake in Collegium Pharmaceutical by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after buying an additional 17,942 shares during the period. Principal Financial Group Inc. increased its stake in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after buying an additional 64,958 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares during the period.

Collegium Pharmaceutical Stock Down 2.3 %

COLL stock opened at $29.58 on Friday. The firm has a 50 day moving average of $36.36 and a 200 day moving average of $35.01. The stock has a market capitalization of $953.96 million, a PE ratio of 12.75 and a beta of 0.95. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 52 week low of $24.61 and a 52 week high of $42.29.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. The trade was a 13.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The trade was a 15.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Truist Financial raised their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Piper Sandler reissued a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. HC Wainwright raised their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.